All In Biotech

Drug Trial Radar · NCT07243340

A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor

A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Herpes Virus C5252 Injection in Patients With Intracranial Tumor

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Apr 3, 2026

Primary completion

Dec 15, 2027

Study completion Dec 15, 2028

Sponsor

Lead sponsor
ImmVira Pharma Co. LtdIndustry
Sponsor type
Industry
First posted
Nov 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study includes phase I dose escalation part and phase IIa dose expansion part. The goal of this clinical trial is to learn if C5252 treatment is safe and well tolerated in patients with intracranial tumor and to learn preliminary efficacy of C5252. In this study, participants will be given single or multiple doses of C5252 according to protocol followed by toxicity observation, safety follow-up and long-term follow-up.

Conditions

  • Glioma, Malignant

Interventions

  • Herpes Virus C5252 InjectionBiological

    C5252 will be administered at designed dose level.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Incidence of adverse eventTime frame: Up to 30 days after completion of treatment
  2. Phase I: Determine the MTD/RP2DTime frame: up to 4 weeks
  3. Phase II: Overall SurvivalTime frame: Up to 2 years
  4. Phase II: OS rateTime frame: Up to 2 years after first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.